Opinion: NEJM sheds light on payments to doctors
It should come as no surprise that pharmaceutical companies pay doctors for a variety of reasons such as research, lecturing, and teaching. Such payments are justified as these physicians tend to be in demand as experts and their expertise is valued. They can't be expected to do this work pro bono – their time is valuable. However, such payments are viewed with great suspicion. Industry critics are quick to charge that what companies are really doing is currying favor with doctors so that they will write more prescriptions for their drugs. This type of "manipulation" is believed to be a conflict-of-interest.
- 'Kafkaesque' Value System Unfairly Penalizes Doctor Pay
- Proton Beam Therapy Poised for Growth in US
- mHealth Tackles Readmissions
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Targeting Self-Insured Populations
- Some Cancer Hospitals' Quality Data Will Soon Be Public
- MA an Insurance Proving Ground for Providers
- 4 Crucial Tactics for Reining in Healthcare Cost
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- Docs Fret as HHS Addresses Malpractice Reporting 'Loopholes'